Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease

Mazen M. Dimachkie*, Richard J. Barohn, Barry Byrne, Ozlem Goker-Alpan, Priya S. Kishnani, Shafeeq Ladha, Pascal Laforêt, Karl Eugen Mengel, Loren D.M. Peña, Sabrina Sacconi, Volker Straub, Jaya Trivedi, Philip Van Damme, Ans T. Van Der Ploeg, John Vissing, Peter Young, Kristina An Haack, Meredith Foster, Jane M. Gilbert, Patrick MiossecOlivier Vitse, Tianyue Zhou, Benedikt Schoser

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
4 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Psychology